Fuller & Thaler Asset Management Inc. Sells 390,724 Shares of Haemonetics Corporation (HAE)
Fuller & Thaler Asset Management Inc. trimmed its holdings in shares of Haemonetics Corporation (NYSE:HAE) by 17.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,829,273 shares of the medical instruments supplier’s stock after selling 390,724 shares during the quarter. Fuller & Thaler Asset Management Inc. owned 3.48% of Haemonetics Corporation worth $82,079,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also made changes to their positions in the company. Victory Capital Management Inc. raised its position in Haemonetics Corporation by 18.7% in the 3rd quarter. Victory Capital Management Inc. now owns 2,414,526 shares of the medical instruments supplier’s stock worth $108,340,000 after purchasing an additional 381,012 shares during the period. HealthCor Management L.P. raised its position in Haemonetics Corporation by 15.9% in the 2nd quarter. HealthCor Management L.P. now owns 1,854,872 shares of the medical instruments supplier’s stock worth $73,249,000 after purchasing an additional 254,872 shares during the period. Wells Fargo & Company MN raised its position in Haemonetics Corporation by 9.3% in the 2nd quarter. Wells Fargo & Company MN now owns 2,788,122 shares of the medical instruments supplier’s stock worth $110,104,000 after purchasing an additional 238,294 shares during the period. Anchor Capital Advisors LLC raised its position in Haemonetics Corporation by 41.7% in the 2nd quarter. Anchor Capital Advisors LLC now owns 774,906 shares of the medical instruments supplier’s stock worth $30,601,000 after purchasing an additional 227,941 shares during the period. Finally, Arrowstreet Capital Limited Partnership purchased a new stake in Haemonetics Corporation in the 2nd quarter worth about $6,115,000.
In related news, CFO Willaim P. Burke sold 13,193 shares of the firm’s stock in a transaction on Tuesday, November 14th. The shares were sold at an average price of $54.04, for a total transaction of $712,949.72. Following the sale, the chief financial officer now owns 27,227 shares in the company, valued at $1,471,347.08. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Ronald G. Gelbman sold 5,440 shares of the firm’s stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $56.69, for a total transaction of $308,393.60. The disclosure for this sale can be found here. In the last ninety days, insiders sold 40,250 shares of company stock valued at $2,196,240. Corporate insiders own 1.20% of the company’s stock.
Shares of Haemonetics Corporation (HAE) traded down $0.29 on Tuesday, reaching $57.70. 613,600 shares of the company’s stock traded hands, compared to its average volume of 352,250. The firm has a market capitalization of $3,062.93, a P/E ratio of 35.58, a price-to-earnings-growth ratio of 4.36 and a beta of 0.91. Haemonetics Corporation has a 52 week low of $36.44 and a 52 week high of $58.23. The company has a current ratio of 2.17, a quick ratio of 1.51 and a debt-to-equity ratio of 0.22.
Haemonetics Corporation (NYSE:HAE) last announced its earnings results on Tuesday, November 7th. The medical instruments supplier reported $0.48 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.41 by $0.07. The company had revenue of $225.40 million during the quarter, compared to the consensus estimate of $219.12 million. Haemonetics Corporation had a net margin of 0.50% and a return on equity of 11.16%. Haemonetics Corporation’s revenue was up 2.3% compared to the same quarter last year. During the same period last year, the firm earned $0.38 earnings per share. research analysts anticipate that Haemonetics Corporation will post 1.7 earnings per share for the current fiscal year.
HAE has been the topic of a number of recent analyst reports. Zacks Investment Research raised shares of Haemonetics Corporation from a “hold” rating to a “buy” rating and set a $52.00 price objective on the stock in a research report on Wednesday, October 25th. Jefferies Group LLC reissued a “buy” rating and issued a $48.00 price objective on shares of Haemonetics Corporation in a research report on Thursday, July 27th. BidaskClub lowered shares of Haemonetics Corporation from a “sell” rating to a “strong sell” rating in a research report on Thursday, July 27th. Morgan Stanley restated an “equal weight” rating and issued a $43.00 target price (up from $38.00) on shares of Haemonetics Corporation in a research note on Friday, October 6th. Finally, Craig Hallum restated a “hold” rating and issued a $50.00 target price (up from $40.00) on shares of Haemonetics Corporation in a research note on Wednesday, November 8th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company. Haemonetics Corporation currently has a consensus rating of “Hold” and a consensus target price of $53.33.
Haemonetics Corporation Company Profile
Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.
Receive News & Ratings for Haemonetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.